Lenalidomide in multiple myeloma.

Abstract

In the last couple of years major progress has been made in the treatment of multiple myeloma (MM) through the introduction of novel agents like thalidomide, lenalidomide, bortezomib and pomalidomide, mostly in combination with autologous stem cell transplantation. Lenalidomide, a second-generation immunomodulatory agent with antitumor and immunomodulatory effects against MM, in combination with dexamethasone was proven to show significant clinical benefits (overall survival and progression-free survival) in Phase III trials either as induction or as maintenance therapy. With a manageable toxicity profile, lenalidomide seems to be an attractive agent in the treatment of MM. Here, we discuss the present data and research on lenalidomide in the treatment of MM.

• Authors: Young Kim, Ingo G H Schmidt-Wolf
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 15 Issue 5 Pg. 491-7 (May 2015) ISSN: 1744-8328 [Electronic] England
• PMID: 25843431 (Publication Type: Journal Article, Review)

Chemical References

• Immunologic Factors
• Thalidomide
• Dexamethasone
• Lenalidomide

Topics

• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Combined Modality Therapy
• Dexamethasone (administration & dosage)
• Disease-Free Survival
• Humans
• Immunologic Factors (adverse effects, therapeutic use)
• Lenalidomide
• Multiple Myeloma (drug therapy, pathology)
• Stem Cell Transplantation (methods)
• Survival Rate
• Thalidomide (administration & dosage, analogs & derivatives)